Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-12-05
|
solithromycin |
community-acquired bacterial pneumonia (CABP) |
3 |
Cempra (USA - NC) Toyama Chemical (Japan) |
Infectious diseases |
2016-12-05
|
CTX DP (human neural stem cell product) |
acute stroke |
2 |
Reneuron (UK) |
Cerebrovascular diseases |
2016-12-05
|
KY1005 |
acute graft-versus-host-disease (GvHD) |
preclinical |
Kymab (UK) |
Transplantation |
2016-12-05
|
axicabtagene ciloleucel (KTE-C19 (autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor) |
acute lymphoblastic leukemia (ALL) |
1-2 |
Kite Pharma (USA - CA) |
Cancer - Oncology |
2016-12-04
|
GBT440 |
sickle cell disease |
1-2 |
Global Blood Therapeutics (USA - CA) |
Rare diseases - Genetic diseases - Hematological diseases |
2016-12-04
|
AG-519 |
pyruvate kinase deficiency, anemia |
1 |
Agios Pharmaceuticals (USA -MA) |
Hematological diseases |
2016-12-04
|
APRIL based chimeric antigen receptor |
|
preclinical |
Autolus (UK) |
Cancer - Oncology |
2016-12-03
|
JCAR014 |
relapsed or refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) |
1 |
Juno Therapeutics (USA - WA) |
Cancer - Oncology |
2016-12-03
|
JCAR014 |
chronic lymphocytic leukemia (CLL) |
1-2 |
Juno Therapeutics (USA - WA) |
Cancer - Oncology |
2016-12-03
|
AFM13 |
|
preclinical |
Affimed (Germany) |
Cancer - Oncology |
2016-12-03
|
Ery-asp®/Graspa® (eryaspase - L-asparaginase loaded erythrocytes) |
|
preclinical |
Erytech Pharma (France) |
Cancer - Oncology |
2016-12-03
|
TNT009 - humanised IgG4 monoclonal antibody against total complement component 1, subcomponent s |
bullous pemphigoid (BP), cold agglutinin disease, warm autoimmune hemolytic anemia, end-stage renal disease (ESRD) |
1 |
True North Therapeutics (USA - CA) |
Rare diseases - Autoimmune diseases - Hematological diseases |
2016-12-03
|
CMV-CTL |
refractory cytomegalovirus (CMV) chorioretinitis, meningoencephalitis |
2 |
Atara Biotherapeutics (USA - CA) |
Infectious diseases |
2016-12-02
|
IMCgp100 |
uveal melanoma |
1 |
Immunocore (UK) |
Cancer - Oncology |
2016-12-02
|
Vonvendi®(recombinant von Willebrand Factor) |
von Willebrand disease |
3 |
Shire (UK - USA) |
Rare diseases - Genetic diseases - Hematological diseases |
2016-12-02
|
OV101 (gaboxadol - 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol) |
Angelman Syndrome |
2 |
Ovid Therapeutics (USA - NY) |
Rare diseases - Genetic diseases - Neurological diseases |
2016-12-01
|
omecamtiv mecarbil |
heart failure |
3 |
Amgen (USA - CA) Cytokinetics (USA - CA) Servier (France) |
Cardiovascular diseases |
2016-11-30
|
omecamtiv mecarbil |
chronic heart failure |
2 |
Amgen (USA - CA) |
Cardiovascular diseases |
2016-11-30
|
monalizumab (IPH2201) |
ovarian cancer |
1 |
Innate Pharma (France) the Canadian Cancer Trials Group (CCTG) (Canada) |
Cancer - Oncology |
2016-11-29
|
Resunab™- JBT-101 - (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-Dibenzo(b,d)pyran-9-carboxylic acid |
dermatomyositis |
2 |
Corbus Pharmaceuticals (USA - MA) |
Dermatological diseases - Inflammatory diseases |